Gururangan, Sridharan

Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)

Gajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., Mahajan, A., Su, J., Bouffet, E., Bartels, U., et al. (2021) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentNeuroblastoma Research and Treatments

Cited by 241

Phase I Trial of MK-0752 in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study

Fouladi, M., Stewart, C. F., Olson, J., Wagner, L. M., Onar-Thomas, A., Kocak, M., Packer, R. J., Goldman, S., Gururangan, S., Gajjar, A., et al. (2011) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentAcute Lymphoblastic Leukemia research

Cited by 164

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: safety, efficacy, biomarker, and pharmacokinetics – CheckMate 908

Dunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., et al. (2023) · Neuro-Oncology

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 73

Sluggish cognitive tempo in survivors of pediatric brain tumors

Willard, V. W., Hardy, K. K., Allen, T. M., Hwang, E. I., Gururangan, S., Hostetter, S. A., & Bonner, M. J. (2013) · Journal of Neuro-Oncology

Childhood Cancer Survivors' Quality of LifeCancer-related cognitive impairment studies

Cited by 36